*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2025 | Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity The New England journal of medicine · human | PMID 40544433 |
| 2025 | Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes The New England journal of medicine · human | PMID 40544432 |
| 2025 | Emerging pharmacotherapies for obesity: A systematic review Pharmacological reviews · preclinical | PMID 39952695 |
| 2025 | What is the pipeline for future medications for obesity? International journal of obesity (2005) · preclinical | PMID 38302593 |
| 2025 | Weight management treatment in obesity Medicina clinica · preclinical | PMID 40865172 |
| 2024 | Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis BMJ (Clinical research ed.) · preclinical | PMID 38286487 |
| 2024 | Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis Indian journal of endocrinology and metabolism · preclinical | PMID 39676787 |
| 2024 | Amylin analogs for the treatment of obesity without diabetes: present and future Expert review of clinical pharmacology · preclinical | PMID 39317404 |
| 2024 | Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity Cardiology in review · preclinical | PMID 36883831 |
| 2023 | Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial Lancet (London, England) · human | PMID 37364590 |
| 2022 | Drugs for Treating Obesity Handbook of experimental pharmacology · preclinical | PMID 34783910 |
| 2021 | Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial Lancet (London, England) · human | PMID 34798060 |
Cagrilintide (Cagrilintide (long-acting amylin analogue)). Long-acting amylin receptor agonist. Slows gastric emptying and promotes satiety; investigated alone and combined with semaglutide (CagriSema).
Commonly discussed uses: investigational obesity (trials, incl. CagriSema combination). There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Long-acting amylin receptor agonist. Slows gastric emptying and promotes satiety; investigated alone and combined with semaglutide (CagriSema).
Reported considerations: GI: nausea, vomiting (dose-related in trials), long-term safety under study. There is both human and animal/preclinical research, though the depth and quality vary by indication. Investigational. Not approved. Grey-market sale is unverified material. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low trial titration, typical investigational (e.g. 2.4mg/week in trials), high trial-defined. Administration: subcutaneous. Half-life: ~7-8 days (long-acting).
Australian status: Investigational — not approved. Investigational. Not approved. Grey-market sale is unverified material. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: research vials vary; storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): investigational; CagriSema (with semaglutide) in trials. Stacking increases interaction/safety uncertainty.